Skip to main content

Table 2 Summary of clinical response in relation to KRAS mutational status.

From: Low Percentage of KRAS Mutations Revealed by Locked Nucleic Acid Polymerase Chain Reaction: Implications for Treatment of Metastatic Colorectal Cancer

 

RP/RC

SD

PD

Total

All

29 (30.5%)

37 (38.9%)

29 (30.5%)

95

WT/WT

23 (36.5%)

22 (34.9%)

18 (28.6%)

63

WT/mutated

6 (18.75%)

15 (46.85%)

11 (34.4%)

32